1. Home
  2. VCIG vs VRAX Comparison

VCIG vs VRAX Comparison

Compare VCIG & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VCI Global Limited

VCIG

VCI Global Limited

HOLD

Current Price

$0.22

Market Cap

2.4M

ML Signal

HOLD

Logo Virax Biolabs Group Limited

VRAX

Virax Biolabs Group Limited

HOLD

Current Price

$3.19

Market Cap

2.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VCIG
VRAX
Founded
2013
2013
Country
Malaysia
United Kingdom
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4M
2.3M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
VCIG
VRAX
Price
$0.22
$3.19
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$1.00
AVG Volume (30 Days)
836.8K
470.4K
Earning Date
05-08-2026
06-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$217,274.83
Revenue Next Year
N/A
N/A
P/E Ratio
$1.81
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.20
$0.10
52 Week High
$23.40
$13.19

Technical Indicators

Market Signals
Indicator
VCIG
VRAX
Relative Strength Index (RSI) 26.02 55.43
Support Level $0.20 $0.19
Resistance Level $1.14 $4.75
Average True Range (ATR) 0.03 0.29
MACD 0.10 0.01
Stochastic Oscillator 6.66 31.65

Price Performance

Historical Comparison
VCIG
VRAX

About VCIG VCI Global Limited

VCI Global Ltd is a holding company. The principal activities of the Company and its subsidiaries are the provision of business Strategy consultancy and technology development. The firm organized its consulting services into three main segments: Business Strategy Consultancy; Technology development, solutions and consultancy; and Others. It derives the majority of its revenue from the Business Strategy Consultancy segment, which focuses on listing solutions, investor relations, and boardroom strategies consultancy.

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.

Share on Social Networks: